This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Idenix Pharmaceuticals' CEO Presents At Morgan Stanley Global Healthcare Conference (Transcript)

We made the decision about five or six years ago to focus almost exclusively on HCV and direct-acting antivirals in HCV. And a lot of that came really out of our expertise and our core competencies in nucleoside chemistry. The company was really founded on its nucleoside chemistry base and we’ve continued to build upon that since the company’s inception back in 1998.

So right now our lead program is IDX184. I know we’ll talk a little bit about some of the things that have been going on with that program over the last four to six weeks. But this is a nucleotide prodrug that we’ve just completed enrollment in a Phase IIB study on, and patients are continuing on on the peg/riba part of that. We have a next generation nucleotide prodrug called IDX19368 that we have filed an IND on, and we’ll talk a little bit more about that in the way of the recent FDA clinical hold.

And then our other program right now, which we’re very excited about is IDX719, which is a next generation NS5A inhibitor that we recently completed a proof of concept study on across all four genotypes, genotypes 1, 2, 3, and 4. Had very nice data on that, and we look forward to moving that into the next stage of clinical development.

Question-and-Answer Session

David Friedman - Morgan Stanley

That’s great. So maybe if we can just start with a couple of broad questions quickly. Number one is, can you just update people on your cash position and whether you have any debt?

Ronald Renaud

Sure. Just purely from a housekeeping perspective, we just completed a financing in early August where we raised just under $200 million. We had, at the end of the second quarter, just under $80 million, so this leaves us in a very good cash position from a balance sheet perspective. We carry no debt. Our balance sheet is very, very straightforward.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,560.73 +120.14 0.69%
S&P 500 2,082.81 +15.17 0.73%
NASDAQ 5,063.6090 +23.8330 0.47%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs